Top Tweets for #ExpandedAccessProgram
These are a few of the ongoing & new GIST clinical trials & programs currently enrolling. If you have questions or need help navigating a #ClinicalTrial, contact: Simran, [email protected] #KQB198 #PEMIGIST #Pemigatinib #StrateGIST3 #ExpandedAccessProgram #Bezuclastinib
Really……..kinda wish it was……..
The only takeaway is that this patient suffers from #USH2A gene mutation 🧬
Under #FDA #ExpandedAccessProgram this is/will validate the scientific clinical gene-agnostic hypothesis for treating #RetinitisPigmentosa
#OCU400 $OCGN
#OCU400 EAP - should not deter, inhibit, or preclude #Ocugen from treating patients, it should ensure they #TreatEveryone
Given that some patients were not followed up following initial trials & EAP communications.
#RightToTry #CompassionateUse #ExpandedAccessProgram
$OCGN
I’ve signed 100% of compassionate use requests that have come to my desk.
What about- Did you know? There is an Expanded Access Program that gives advanced GIST patients who’ve progressed on imatinib access to #bezuclastinib + #sunitinib. For more information: https://t.co/KAS9XxIAFW
#EAP #GISTEducation #ExpandedAccessProgram #clinicaltrials
💡 $BCLI’s #ExpandedAccessProgram (EAP) suggests >96% probability that NurOwn® improves survival in #ALS. A powerful step forward in #neurodegenerativedisease treatment. 🌟Read our #ACFResearch update note https://t.co/F9rIxRT64p @MinoShah @Cylebo @ChrisPalmerMD @LongevityTech
$BCLI's compassionate use study (Expanded Access Program), delivered >96% probability that BCLI’s #NurOwn® treatment was responsible for an improved survival rate in a test group of 10 ALS patients + 100 sufferers comparative cohort.🌟 Read our analysis here https://t.co/EQt5ZHTbas. #StemCellTherapy #BCLI #Biotech #Investment #ALS #BCLI $AZN $AMGN $SNY $GILD $VRTX $ABBV $AMRX $ROG.SW $MRK $PFE $TEVA $NVS $BIIB. @BrainstormCell @Cylebo @NeuroscienceNew @pknoepfler @LongevityTech @FonsieTrader @ChrisPalmerMD @bsw5020


aTyr announces #ExpandedAccessProgram for #efzofitimod for #pulmonarysarcoidosis. Individual Patient EAP intends to allow access for patients who complete Phase 3 EFZO-FIT™ study & wish to receive treatment with efzofitimod outside of the clinical trial. https://t.co/sfcVRjdjov

Have a question about #CompassionateUse or #RightToTry? Wondering if you qualify for an #ExpandedAccessProgram? Reply HERE or DM to submit questions to the panel ahead of time and tune in on 4/12 to hear their responses.
#ouralscommunity took a tough blow today but let it be known that today also starts my year with #Pridopidine on #expandedaccessprogram
“Expanded access is a pathway for a patient with an immediately life-threatening condition to gain access to an investigational medical

@Fatih_AKTAŞ
@BiotchPharmaTurkey Pharmaceutical Marketing and Consulting Services
#RareDiseases
#OrphanDrugs
#EarlyAccessProgramEAP
#NamedPatientProgramNPP
#ExpandedAccessProgram
#StartUp
#SalesMarketing
#MarketAccess
#CountryLead
#NicheArea
OncoSec is committed to delivering safer and more effective #cancer treatments that can provide long-term benefits for patients. Learn more about our #ExpandedAccessProgram here: https://t.co/ihyInQTLM3

#Oblato Announces that it has received a Positive Response from the #FDA for the use of #OKN007 for patients with high-grade #Gliomas in an #ExpandedAccessProgram https://t.co/R8lglbk1Ku
#CompassionateUse is the marriage of the humanity of Right to Try & the science of the #FDA. The #ACTforALS empowers the FDA's existing #ExpandedAccessProgram to get #DrugsinBodies while increasing data for researchers
Without it, people w #ALS are #DyingWaiting
#ALSAwareness
My husband and I fought for continued access to treatment and to improve an archaic regulatory pathway. He died waiting for change, writes Nicole Cimbura https://t.co/B14i1ygMvS
Our #ExpandedAccessProgram Management team helps you to reach your patients who need time-sensitive, investigational medical products. Learn how we deliver a potential pathway, establishing alternative #transportsolutions, for your #patients. https://t.co/YdZ3fEznBn

#Oncopeptides initiates U.S. #ExpandedAccessProgram with #Melflufen in triple-class refractory #MultipleMyeloma https://t.co/XUZ5f13HeW
We've initiated a rolling NDA submission for maralixibat for cholestsatic pruritus assoc. with #ALGS, & launched our #expandedaccessprogram. We're striving to make a meaningful impact on the lives of ALGS patients & families & today is a big step forward! https://t.co/xHLFV42NFT

Want information on how to access treatment options through the FDA’s #expandedaccessprogram? Read our newest blog, "Expanded Access vs. Right to Try" to get the details you need: https://t.co/9lvLrdWcQ1 #cancercare #clinicaltrials

The @US_FDA #ExpandedAccessProgram experience with #CCP: preliminary report of 5000 (mostly severe) #COVID19 patients (no parallel controls):
0.7% adverse event rate, 15% 7d mortality.
(Funding from the @MayoClinic, 🏀🗑️@NBA, @NIAIDFunding, and more).
https://t.co/OTTkbuGEBi
UPDATE-Gilead #ExpandedAccessProgram for #remdesivir site selection for #COVID19 pts in progress. Pearls 1)email [email protected] 2)sites will be selected based if surge, poor remdesivir #RCT access, regional reach & regulatory compliance. Stay tuned
Last Seen Hashtags on Sotwe
Most Popular Users

Elon Musk 
@elonmusk
240.1M followers

Barack Obama 
@barackobama
119.3M followers

Donald J. Trump 
@realdonaldtrump
111.6M followers

Cristiano Ronaldo 
@cristiano
108.7M followers

Narendra Modi 
@narendramodi
106.9M followers

Rihanna 
@rihanna
97.2M followers

NASA 
@nasa
92.1M followers

Justin Bieber 
@justinbieber
90.5M followers

KATY PERRY 
@katyperry
86.7M followers

Taylor Swift 
@taylorswift13
80.5M followers

Lady Gaga 
@ladygaga
72.1M followers

Kim Kardashian 
@kimkardashian
69.3M followers

YouTube 
@youtube
68.6M followers

Virat Kohli 
@imvkohli
68.4M followers

Bill Gates 
@billgates
63.3M followers

The Ellen Show
@theellenshow
62.5M followers

CNN 
@cnn
61.9M followers

Neymar Jr 
@neymarjr
60.9M followers

X 
@x
60.9M followers

CNN Breaking News 
@cnnbrk
59.9M followers





















